William Blair & Company
SPRY icon

William Blair & Company’s ARS Pharmaceuticals SPRY Stock Holding History

William Blair & Company’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,825
Closed -$86.9K – 2059
2026
Q1 		$86.9K Sell
10,825
-775
-7% -$7.43K ﹤0.01% 1615
2025
Q4 		$135K Buy
+11,600
New +$113K ﹤0.01% 1526

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

William Blair & Company's SPRY Position: Q2 2026 in Review

William Blair & Company sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 10,825 shares — an estimated $86.9K sold.

William Blair & Company first reported a position in SPRY in Q4 2025 and held it in 2 quarters. The position peaked at $135K in Q4 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • William Blair & Company reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • William Blair & Company sold 10,825 ARS Pharmaceuticals shares in Q2 2026, an estimated $86.9K.
  • William Blair & Company first reported a position in ARS Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • William Blair & Company's ARS Pharmaceuticals position peaked at $135K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.